Compare Immunovant Inc. Common Stock (IMVT) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Materials Select Sector SPDR Fund — how do they compare? Immunovant Inc. Common Stock trades at $30.47 (market cap $6.25B), while Materials Select Sector SPDR Fund trades at $49.47 (market cap $7.73B). The key difference: Materials Select Sector SPDR Fund is the larger of the two by market cap, and Materials Select Sector SPDR Fund is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 1 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| IMVT | XLB | |
|---|---|---|
Market Cap | $6.25B | $7.73B |
Volume | 1,755,411 | 13,681,146 |
Sector | Health | — |
52-Week High | $44.96 | $53.67 |
52-Week Low | $17.03 | $42.23 |
Typical Hold Time | 1 Days | 70 Days |
Enterprise Value | $5.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLB, the Materials Select Sector SPDR ETF, trades at $49.55, up 1.16% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The fund is heavily concentrated in chemicals (49% of assets) and faces cyclical pressures, with recent news highlighting sector volatility amid AI-driven infrastructure demand. Key support sits at $48, while resistance is at $50.
The outlook for XLB is cautious due to sector overvaluation concerns and bearish technicals. Opportunities lie in long-term infrastructure trends, but risks include economic sensitivity and high concentration. Investors should weigh cyclical exposure against potential growth from manufacturing and AI-related material demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
